Abatacept
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Sep 30, 2016 → Jan 31, 2018
NCT ID
NCT02037737About Abatacept
Abatacept is a pre-clinical stage product being developed by Bristol Myers Squibb for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02037737. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05170672 | Pre-clinical | Completed |
| NCT05981976 | Phase 1 | Completed |
| NCT04925375 | Phase 2 | Recruiting |
| NCT04472494 | Phase 2 | Terminated |
| NCT04477642 | Phase 1/2 | Withdrawn |
| NCT03924401 | Phase 2 | Active |
| NCT03882008 | Approved | Completed |
| NCT03669861 | Phase 2 | Completed |
| NCT03714022 | Phase 1 | Completed |
| NCT03084419 | Phase 2 | UNKNOWN |
| NCT03215927 | Phase 2 | Completed |
| NCT02915159 | Phase 3 | Completed |
| NCT02805010 | Phase 1 | UNKNOWN |
| NCT02037737 | Pre-clinical | Completed |
| NCT02592798 | Phase 2 | Completed |
| NCT02598466 | Pre-clinical | Completed |
| NCT02281058 | Phase 1 | UNKNOWN |
| NCT02078882 | Approved | Completed |
| NCT01954979 | Phase 1 | Completed |
| NCT02169544 | Pre-clinical | Completed |
Competing Products
20 competing products in Rheumatoid Arthritis